Contact
      Please use this form to send email to PR contact of this press release:
      
      VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial
    
      TO:
      
      
      
      
      
      
      
    
      Please use this form to send email to PR contact of this press release:
      
      VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial
    
      TO: